William J. Chase - 14 Apr 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: Director
Signature: /s/ James Basta, Attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 14 Apr 2023
Net transactions value: $0
Form type: 4
Filing time: 18 Apr 2023, 17:04:44 UTC
Next filing: 16 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+10,483	+154%	$0.000000	17,283	14 Apr 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (Right to Buy)	Award	$0	+14,931		$0.000000	14,931	14 Apr 2023	Common Stock	14,931	$38.16	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	This option was granted on April 14, 2023 with respect to 14,931 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on April 14, 2024 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter.